fbpx

Phamamar achieve to extend the comercialization of its marine derived anti cancer drugs over eleven latinamerican countries.

PharmaMar, world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs, announced yesterday the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A., company with headquartes in Viene, Austria, and expert in the latinoamerican rare diseases market.

The signing allows Pint Pharma to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in 11 latinoamerican countries: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela.

According to the agreement, Pint will pay undisclosed milestone and royalty payments to PharmaMar in exchange for the rights to register, commercialize and distribute Aplidin® in each of the foresaid territories. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.

The Company announced at the ASH Congress during December 2017, in San Diego (USA), the results in a pivotal Phase III clinical trial (ADMYRE) with plitidepsin, where the primary endpoint, progression free survival, and secondary objectives, overall survival and safety were met; providing the treatment for multiple myeloma with a novel mechanism of action.

According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, “we are about to address our first strategic alliance with Pint Pharma International for the commercialization of Aplidin®, developed to tackle Multiple Myeloma. This agreement is aligned with our commitment to bring novel and first-in-class therapies to patients worldwide.”

David Muñoz, CEO of Pint Pharma, stated that “we are excited with the opportunity of including Aplidin® into our comprehensive hematology oncology portfolio; this will further strengthen our mission to enable the Latin American population with severe life-altering conditions to live better lives by providing early and efficient access to innovative therapeutic solutions”.

Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It specifically binds to eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death). The bind of plitidepsina to eEF1A2 blocks its pro-oncogenic property and avoids the transport of the badly sequenced proteins (which are toxic for the tumor) to the proteasome, preventing by this way their destruction. Also it prevents the activation of the agresome by eEF1A2 and its destruction in the lisosome. This provokes an excess of proteins badly sequenced and the cellular death by apoptosis. Other treatments are complementary to plitidepsina and block the proteasome or the cereblon which identifies the proteins badly sequenced.

Tunicate Aplidium albicans and structure of Aplidin/Plitidepsin.

Plitidepsin has seen its marketing authorization application accepted by the EMA in Q4 2016 in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma. It is in clinical development for other hematological cancers, including a Phase Ib trial in relapsed or refractory multiple myeloma as a triple combination of plitidepsin, bortezomib and dexamethasone, and a Phase II study in relapsed or refractory angioimmunoblastic T-cell lymphoma.

It has also received orphan drug designation in the European Union and the United States of America.

 

The bind of plitidepsina to eEF1A2 blocks its pro-oncogenic property and avoids the transport of the badly sequenced proteins (which are toxic for the tumor) to the proteasome, preventing by this way their destruction. Also it prevents the activation of the agresome by eEF1A2 and its destruction in the lisosome. This provokes an excess of proteins badly sequenced and the cellular death by apoptosis. Other treatments are complementary to plitidepsina and block the proteasome or the cereblon which identifies the proteins badly sequenced.

 

 

 

 

 

 

 

 

 

 

About Pint Pharma and PharmaMar. Pint Pharma strives to be the first Pan-Latin American provider of innovative and high value-added treatments within Oncology, Rare Diseases and Specialty Care. Is a private, Latin American focused pharmaceutical company, devoted to the development, registration and commercialization of specialty based treatments. Pint Pharma benefits from leaders with extensive experience in the pharmaceutical sector and who are based strategically throughout Latin America and Europe. This company has a long track record of developing strong relationships with global pharmaceutical and healthcare companies.

 PharmaMar, Headquartered in Madrid, is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin, plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

More Stories
Have you heard about “in vitro cultured meat”? Discover how they can relieve the conventional ranching from its position.